Showing 71-80 of 10219 results for "".
Fractional Lasers for NMSC and More
https://practicaldermatology.com/conferences/scale-2025/fractional-lasers-for-nmsc-and-more/35876/Joel L. Cohen, MD, FAAD, and Matthew M. Avram, MD, talk about research involving fractional lasers, including as part of combination treatments for nonmelanoma skin cancer, at Music City SCALE 2025.Staphylococcus aureus Colonization
https://practicaldermatology.com/issues/september-2025/staphylococcus-aureus-colonization/37626/In a recent review article, Piewngam and Otto examined the epidemiology, mechanisms, and clinical implications of Staphylococcus aureus (S. aureus) colonization, while evaluating both current and emerging strategies for decolonization.Intergenerational Dermatology: Two Generations of Dermatologists Reflect on the Field
https://practicaldermatology.com/topics/general-topics/intergenerational-dermatology-two-generations-of-dermatologists-reflect-on-the-field-2/23937/With Heidi A. Waldorf, MD, and Donald S. Waldorf, MDContact Derm and AD Updates
https://practicaldermatology.com/conferences/maui-derm-2022/contact-derm-and-ad-updates/20052/Matthew Zirwas, MD reviews allergens that have made the list of Allergen of the Year over the program's 20-year history and what dermatologists should know about these allergens. He also provides an overview of his approach to diagnosing and treating atopic dermatitis.ISDPA: Dr. Bhatia and Dr. Zirwas Discuss the Itchy Patient
https://practicaldermatology.com/conferences/isdpa-midwest-derm-2024/isdpa-dr-bhatia-and-dr-zirwas-discuss-itchy-patient/27065/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, talks with Matthew Zirwas, MD, about Dr. Zirwas’s lecture on the itchy patient and the latest solutions for itch at the Illinois Society of Dermatology Physician Assistants (ISDPA) Midwest Dermatology Conference 2024.Tolerability of JAK Inhibitors Used in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/tolerability-of-jak-inhibitors-used-in-dermatology/20126/Although safety and tolerability are often intertwined, they are distinct considerations. Topical and oral JAKs used in dermatology today seem to offer good tolerability. Adelaide A. Hebert, MD and Matthew Zirwas, MD discuss potential side effects, management, and monitoring in pediatric and adult pEczematous Dermatitis: Dr. Zirwas
https://practicaldermatology.com/programs/practical-dermatology/eczematous-dermatitis-dr-zirwas/32689/Matthew Zirwas, MD, talks about the therapeutic strategies for non-atopic dermatitis—particularly hand dermatitis and facial dermatitis—that he covered during "Eczematous Dermatitis Update 2025: Contact, Hand, Head and Neck, Eyelid and More" at Maui Derm 2025.Updates from CSF 2017
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-updates-from-csf-2017/18371/Dermatologists and core cosmetic physicians shared new insights and reviewed the developments in clinical and cosmetic dermatology at the ninth annual Cosmetic Surgery Forum in Las Vegas. Matthew Zirwas, MD addressed interest in oral supplements to support skin health. Neurotoxin pioneer Nick Lowe,Journal Club: Dupilumab and Risk of Malignancy
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-dupilumab-and-risk-of-malignancy/32398/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Matthew Zirwas, MD, about the Journal of Allergy and Clinical Immunology: In Practice article "Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national databaseThe Sernivo Formulation
https://practicaldermatology.com/topics/general-topics/the-sernivo-formulation-/18250/SERNIVO (betamethasone dipropionate) Spray, 0.05% is formulated to provide fast and powerful treatment for adult patients with mild to moderate plaque psoriasis. Dr. Jeffrey S. Fromowitz guides viewers through the mechanisms of SERNIVO in these video chapters.